IDA Foundation, on behalf of the Stop TB Partnership/The Global Drug Facility (GDF), is today launching an Invitation to Bid (ITB) for the supply of Ethambutol 100mg dispersible tablets for the treatment of drug-sensitive forms of tuberculosis.
Just over a year after the start of the corona pandemic it is clear that covid-19 has had a devastating impact on the progress of existing tuberculosis (TB) programmes. For latent and progressive infectious diseases, such as TB, early diagnosis and treatment are essential.
IDA Foundation, on behalf of the Stop TB Partnership/The Global Drug Facility (GDF), is today launching an Invitation to Bid (ITB) for the supply of ANTI-TUBERCULOSIS MEDICINES AND RELATED PRODUCTS for the treatment of DRUG-RESISTANT FORMS of tuberculosis to eligible manufacturers.
On Monday July 6, Johnson & Johnson announced a price reduction of the anti-tuberculosis medicine bedaquiline, for low- and middle-income countries. Thanks to the support of USAID and the Global Fund, this price reduction could be achieved. The price dropped from $400 to $340 for a six-month treatment regimen.
As the Corona virus pandemic spreads around the globe, and all health care systems and governments seem to be engulfed with battling COVID-19, we realise it is more important than ever that we don’t lose sight of other existing health issues.
While coronavirus (COVID-19) dominates the news, we need to remember that another respiratory disease kills 1.5 million people per year: tuberculosis (TB). This is an opportunity to unite forces in the fight against TB and coronavirus.
As procurement agent for Stop TB /GDF, we are glad to share this news update as announced by the Stop TB partnership during the 50th Union Conference for Lung Health in Hyderabad, India.
Plus de 3000 professionnels de la santé participeront à la 49e Conférence mondiale sur la santé respiratoire à La Haye: du 24 au 27 octobre 2018.